[18F]florbetaben is a special type of imaging agent used in a PET scan, which is a kind of medical imaging test. In this clinical trial, it helps doctors see if there are any unusual protein deposits in the heart, which can be a sign of a condition called cardiac AL amyloidosis. This imaging agent works by highlighting these protein deposits, making them visible on the PET scan, so doctors can better diagnose the condition. The goal is to see how well this imaging agent can help in accurately diagnosing cardiac AL amyloidosis compared to the usual methods doctors use.

AL Amyloidosis – AL Amyloidosis is a disease where abnormal protein deposits, known as amyloid, accumulate in tissues and organs. These proteins are light chains produced by plasma cells. The disease often affects the kidneys, heart, liver, and nerves. As amyloid builds up, it disrupts normal organ function. Over time, this can lead to organ damage. The progression varies depending on the organs involved and the amount of amyloid deposited.

Cardiac Amyloidosis – Cardiac Amyloidosis is a condition where amyloid proteins are deposited in the heart tissue. This leads to the thickening and stiffening of the heart walls. As the disease progresses, the heart’s ability to pump blood effectively is compromised. This can result in symptoms like fatigue, shortness of breath, and irregular heartbeats. The progression of the disease can lead to heart failure if not managed. The severity and speed of progression can vary among individuals.

ATTR Amyloidosis – ATTR Amyloidosis is characterized by the accumulation of transthyretin amyloid proteins in various organs. This condition can be hereditary or acquired. The amyloid deposits primarily affect the heart and nervous system. As the disease progresses, it can lead to heart problems and nerve damage. Symptoms may include heart failure, neuropathy, and autonomic dysfunction. The rate of progression can differ based on genetic factors and the organs involved.